Oncology Venture after meeting with FDA about cancer drug: "We are close - but not quite over the finish line"
Biotech company Oncology Venture has received positive feedback from the FDA after an introductory meeting about the path to approval for the company's cancer drug. The market potential is DKK 43 billion, but there is a way to go before the Danish company can make its US debut.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
Hørsholm-based biotech company Oncology Venture, which is listed in Sweden, is one step closer to the DKK 40 billion (USD 5.8 billion) market for renal cancer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
